www.forbes.com

www.forbes.com
Share

www.forbes.com

 •  October 14

In 2010, pharmaceutical chemist John Hood had amazing news. The drug giant Sanofi bought TargeGen, the company at which he headed research, for $650 million. That meant fedratinib, a cancer drug he’d co-invented, should have had a smooth path to market. But it wasn’t so. In 2013, Sanofi ended development of fedratinib after cases of Wenicke’s...

www.forbes.com

 •  October 9

Innovation in most businesses can be risky, but it’s uniquely so in the food industry. In the tech sector, the launch of a maps application that sends people to the wrong addresses will annoy customers, for sure. In the fashion industry, the launch of a line of high-waisted jeans may flop, but the losses will be to bottom lines and reputations...

www.forbes.com

 •  September 26

Last week was to have been Puerto Rico Bioscience Innovation Week, the 14th annual celebration of the most-populous U.S. territory's prominence in pharmaceutical biotechnology and medical device manufacturing. Nearly 60 years of collective efforts between industry, governmental and academic institutions created a fertile environment for the...

www.forbes.com

 •  September 26

President Trump will soon issue an executive order to lower drug prices. The order likely will encourage federal health agencies to make greater use of "outcomes-based" contracts. That's great news for patients. These contracts link a drug's price to its effectiveness. If a drug cures or treats patients as advertised, insurers pay the full price....

www.forbes.com

 •  August 8

Imagine you are dying of a disease or condition for which there is no treatment. Or imagine you are dying of a disease or condition for which cures exist, but they are not working for you. If someone said they had an experimental drug that wasn’t approved for sale or use in the United States but that might help you, you’d probably want to try it....

www.forbes.com

 •  July 11

Prescription drug costs are a hot political issue, not as much because of the share of the U.S. health care dollar they consume but because consumers pay a larger share of their drug costs out of pocket than they do for other health care. The lack of price transparency for prescription drugs is a large part of the problem, and making pricing more...

www.forbes.com

 •  July 6

This post was coauthored with Alison Bateman-House, Ph.D., MPH, MA, Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center. If you were dying, surely you would grasp at any chance medicine might offer you. Recently, there has been a lot of effort at the state and federal levels to try to increase patient...

www.forbes.com

 •  July 6

Tweet This When Wall Street has beaten the speculative value out of CARA, it will be time to buy it back. Last week, Cara Therapeutics reported that its phase 2b trial of CR845, an investigational new pain relief drug for patients with Osteoarthritis of the knee or hip, had failed to meet its primary endpoint. Since then, the stock dropped from $26...

www.forbes.com

 •  June 27

Merck announced this morning that anacetrapib, a cholesterol-lowering medicine, reduced heart problems and strokes in a 30,000 patient clinical trial, giving the drug giant a success where Pfizer, Eli Lilly, and Roche have all failed. The full details of the study will be revealed at the annual meeting of the European Society of Cardiology on...

www.forbes.com

 •  June 14

AIF The Innovation Prize for Africa is an initiative of the African Innovation Foundation. While most tests in Africa for infectious diseases can take up to a week to get a result, Liberian doctor Dougbeh Christopher Nyan has invented a prototype that can rapidly detect for three to seven infections in just 10 to 40 minutes. Nyan is one of 10...